share_log

Firefly Neuroscience | 8-K: Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Firefly Neuroscience | 8-K: Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Firefly Neuroscience | 8-K:萤火虫神经科学公布2024年第三季度业绩并提供股东最新情况
美股SEC公告 ·  2024/11/16 00:48

Moomoo AI 已提取核心信息

Firefly Neuroscience announced its Q3 2024 financial results and strategic developments following its successful Nasdaq listing under "AIFF". The company reported a cash position of $1.2 million as of September 30, 2024, with 8,503,365 shares of common stock outstanding as of November 12.The company has established significant partnerships with pharmaceutical companies including Bright Minds Bioscience, Novartis, and Takeda, leveraging its FDA-cleared Brain Network Analytics (BNA™) technology. Notable collaborations include analyzing data for Bright Minds' Phase 2 trial of BMB-101 in epilepsy and supporting Arrivo BioVentures' Phase 1 study of SP-624 for women's depression treatment.Firefly continues to execute its dual commercialization strategy, focusing on supporting US neurologists in patient care and collaborating with pharmaceutical companies for drug development. The company's proprietary database includes over 77,000 EEG scans across twelve disorders, positioning it for growth in both clinical diagnostics and drug development sectors.
Firefly Neuroscience announced its Q3 2024 financial results and strategic developments following its successful Nasdaq listing under "AIFF". The company reported a cash position of $1.2 million as of September 30, 2024, with 8,503,365 shares of common stock outstanding as of November 12.The company has established significant partnerships with pharmaceutical companies including Bright Minds Bioscience, Novartis, and Takeda, leveraging its FDA-cleared Brain Network Analytics (BNA™) technology. Notable collaborations include analyzing data for Bright Minds' Phase 2 trial of BMB-101 in epilepsy and supporting Arrivo BioVentures' Phase 1 study of SP-624 for women's depression treatment.Firefly continues to execute its dual commercialization strategy, focusing on supporting US neurologists in patient care and collaborating with pharmaceutical companies for drug development. The company's proprietary database includes over 77,000 EEG scans across twelve disorders, positioning it for growth in both clinical diagnostics and drug development sectors.
Firefly Neuroscience公布了其2024年第三季度的财务业绩和战略发展,随后其在纳斯达克成功上市,股票代码为"AIFF"。截至2024年9月30日,公司现金状况为120万美元,截至11月12日,共有8,503,365股普通股在外流通。公司与包括Bright Minds Bioscience、诺华和武田在内的药品公司建立了重要的合作关系,利用其获得FDA批准的脑网络分析(BNA™)技术。值得注意的合作包括分析Bright Minds在癫痫治疗中BMB-101的第二阶段试验数据,以及支持Arrivo BioVentures对SP-624用于女性抑郁症治疗的第一阶段研究。Firefly继续执行其双重商业化策略,专注于支持美国神经科医生的患者护理,并与药品公司合作进行药物开发。公司的专有数据库包含超过77,000份EEG扫描,涵盖十二种疾病,为在临床诊断和药物开发领域的增长奠定了基础。
Firefly Neuroscience公布了其2024年第三季度的财务业绩和战略发展,随后其在纳斯达克成功上市,股票代码为"AIFF"。截至2024年9月30日,公司现金状况为120万美元,截至11月12日,共有8,503,365股普通股在外流通。公司与包括Bright Minds Bioscience、诺华和武田在内的药品公司建立了重要的合作关系,利用其获得FDA批准的脑网络分析(BNA™)技术。值得注意的合作包括分析Bright Minds在癫痫治疗中BMB-101的第二阶段试验数据,以及支持Arrivo BioVentures对SP-624用于女性抑郁症治疗的第一阶段研究。Firefly继续执行其双重商业化策略,专注于支持美国神经科医生的患者护理,并与药品公司合作进行药物开发。公司的专有数据库包含超过77,000份EEG扫描,涵盖十二种疾病,为在临床诊断和药物开发领域的增长奠定了基础。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息